Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 651 across all filing types
Latest filing 2019-04-01 Regulatory Filings
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
기타경영사항(특허권취득)(자율공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure (voluntary disclosure) regarding the acquisition of a patent for a cancer immunotherapy biomarker. It does not fit into financial reporting categories like 10-K or IR, nor does it relate to dividends, share transactions, or management changes. As it is a specific regulatory announcement of a corporate event (patent acquisition) that does not fall into the other specialized categories, it is classified as a general regulatory filing.
2019-04-01 Korean
사업보고서 (2018.12)
Audit Report / Information Classification · 99% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'GemVax & KAEL' for the fiscal year ending December 31, 2018. It includes the independent auditor's opinion, financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes to the financial statements. It is not an Annual Report (10-K) as it lacks the comprehensive management discussion and analysis (MD&A) and business overview typical of a full 10-K, and it is not an announcement (RPA) because it contains the full financial data and audit opinion. FY 2018
2019-04-01 Korean
정기주주총회결과(제21기)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal report of the results of an Annual General Meeting (AGM) for the company 'GemVax'. It details the outcomes of shareholder votes on agenda items such as financial statement approval, director and auditor appointments, and business purpose changes. This falls under the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it is the official record of the meeting's resolutions.
2019-03-29 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). This document specifically details changes to the company's board of directors, which falls under the category of Board/Management Information (MANG).
2019-03-29 Korean
감사보고서제출
Regulatory Filings Classification · 95% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filing from the Korean regulatory system (KIND). It provides the auditor's opinion, key financial data (assets, liabilities, profit/loss), and confirms the receipt of the audit report. While it contains financial data, it is a specific regulatory disclosure regarding the completion and submission of the audit, rather than the full Annual Report (10-K) or a standalone audit report document. Given the structure and the nature of the disclosure, it fits best as a Regulatory Filing (RNS) or a report publication announcement, but since it provides the actual audit results summary, RNS is the most appropriate fallback category.
2019-03-21 Korean
기타경영사항(특허권취득)(자율공시)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent by GemVax & Kael. It details the patent name, content, patent holder, and utilization plan. Since this is a regulatory announcement of a specific corporate event (patent acquisition) that does not fit into financial reporting, dividend, or management change categories, it falls under the general regulatory filing category.
2019-03-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.